Krystal Biotech reports Q3 2026 results, VYJUVEK revenue up 30%, $400M buyback authorized

Krystal Biotech reported financial and clinical results for the third quarter ended September 30, 2026, on November 2, 2026. The company recorded $127.3 million in global VYJUVEK net product revenue for the third quarter, an increase of 30% compared to the prior year's third quarter.¹ In the United States, more than 760 reimbursement approvals for VYJUVEK have been secured nationwide.¹

On pricing and reimbursement in Europe, Krystal said pricing negotiations have concluded in Germany and Italy, with an Italian launch expected in early 2027.¹ Talks continue in other European markets and the United Kingdom, with a Spain decision expected later in 2026 and a France decision not before 2027.¹ The company has also filed for marketing authorization in Australia and plans to submit in Switzerland before year end.¹

In the pipeline, Krystal disclosed early data for KB113 in Gorlin syndrome. In a three-patient pilot, multicenter, single-arm, open-label study, more than 80% of assessed basal cell carcinoma lesions showed investigator-assessed clinical regression.¹ Regression occurred in both injected and non-injected lesions, consistent with an abscopal effect.¹ Krystal has opened discussions with the FDA on advancing KB113 into further clinical development for this indication.¹

For KB111 in Hailey-Hailey disease, five patients have been enrolled in the HALITE-1 study, with interim results expected before year end.¹ For KB407 in cystic fibrosis, three more patients are expected to be dosed by year end, with interim results now anticipated in the first half of 2027.¹ In oncology, the company expects to dose about 70 patients at the selected combination regimen in the KYANITE-1 chemotherapy cohort by mid-2027.¹

On capital, cash, cash equivalents and investments totaled $1.2 billion as of September 30, 2026.¹ Krystal's board authorized a share repurchase program of up to $400 million of common stock.¹